The current status of anti GPCR drugs against different cancers

Publication date: Available online 11 January 2020Source: Journal of Pharmaceutical AnalysisAuthor(s): Sana Usman, Maria Khawer, Shazia Rafique, Zara Naz, Komal SaleemAbstractG protein coupled receptors (GPCRs) have been emerged as most potential target for a number of drug discovery programs ranging from control of blood pressure, diabetes, cure for genetic diseases to treatment of cancer. A panel of different ligands including hormones, peptides, ions and small molecules is responsible for activation of these receptors. Molecular genetics have identified key GPCRs, whose mutations or altered expression are linked with tumorgenicity. In this review, we discussed recent advances regarding the involvement of GPCRs in the development of cancers and approaches to manipulate the mechanism behind GPCRs involved tumor growth and metastasis to treat different types of human cancer. This review provides an insight of the current scenario of GPCR-targeted therapy, progress to date and the challenges in the development of anticancer drugs.Graphical abstractGPCRs based drugs against different cancers.
Source: Journal of Pharmaceutical Analysis - Category: Drugs & Pharmacology Source Type: research